Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.38 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.37 |
| ▸ | TUBB | P07437 | 1/20 | 0.37 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2339963 | 1.00 | CYP2C19 (0.42) | CYP2C19KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL3715295 | 0.78 | CYP2A6 (0.44) | KDM4EALDH1A1CYP2A6KMT2A | |
| SCHEMBL3715296 | 0.78 | CYP2A6 (0.44) | KDM4EALDH1A1CYP2A6KMT2A | |
| SCHEMBL196959 | 0.76 | APP (0.52) | CYP2C19KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL2345016 | 0.76 | NFE2L2 (0.48) | ALDH1A1HPGDRAB9ACYP2A6MAPT | |
| SCHEMBL11042248 | 0.76 | APP (0.43) | KDM4E | |
| SCHEMBL3051230 | 0.76 | APP (0.52) | ALDH1A1RAB9AMAPTCYP1B1MEN1 | |
| SCHEMBL11042246 | 0.76 | APP (0.43) | KDM4E | |
| SCHEMBL2345013 | 0.76 | NFE2L2 (0.48) | ALDH1A1HPGDRAB9ACYP2A6MAPT | |
| SCHEMBL11047398 | 0.76 | APP (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023066190-A1 | COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) | 2023-04-27 | — | — | WO | claimed |
| EP-2257297-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF ACNE, SEBORRHOEA AND SEBHORROEIC DERMATITIS, OR FOR REDUCING SEBUM SECRETION | MIMETICA PTY LTD (AU) | 2017-10-18 | — | — | EP | disclosed |
| US-9340517-B2 | Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor | MIMETICA PTY LTD (AU) | 2016-05-17 | — | — | US | disclosed |
| EP-2257534-B1 | 3-AMINOALKYL-1,4-DIAZEPAN-2-ONE MELANOCORTIN-5 RECEPTOR ANTAGONISTS | MIMETICA PTY LTD (AU) | 2013-11-06 | — | — | EP | disclosed |
| US-20130225563-A1 | METHODS OF MODULATING THE ACTIVITY OF THE MC5 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR | MIMETICA PTY LTD (AU) | 2013-08-29 | — | — | US | disclosed |
| US-8377925-B2 | Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor | MIMETICA PTY LTD (AU) | 2013-02-19 | — | — | US | disclosed |
| US-8343958-B2 | 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5-receptor antagonists | MIMETICA PTY LTD (AU) | 2013-01-01 | — | — | US | disclosed |
| US-20120141392-A1 | METHODS OF MODULATING THE ACTIVITY OF THE MC1 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR | MIMETICA PTY LTD (AU) | 2012-06-07 | — | — | US | disclosed |
| US-20110263572-A1 | 3-AMINOALKYL-1,4-DIAZEPAN-2-ONE MELANOCORTIN-5-RECEPTOR ANTAGONISTS | MIMETICA PTY LTD (AU) | 2011-10-27 | — | — | US | disclosed |
| US-8008291-B2 | 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists | MIMETICA PTY LTD (AU) | 2011-08-30 | — | — | US | disclosed |
| US-20090221558-A1 | METHODS OF MODULATING THE ACTIVITY OF THE MC5 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR | Marp Therapeutics Pty Ltd (AU) | 2009-09-03 | — | — | US | disclosed |
| US-20090221557-A1 | 3-AMINOALKYL-1,4-DIAZEPAN-2-ONE MELANOCORTIN-5 RECEPTOR ANTAGONISTS | Marp Therapeutics Pty Ltd (AU) | 2009-09-03 | — | — | US | disclosed |
| US-4487772-A | CARDIOTONIC AGENTS | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 1984-12-11 | — | — | US | disclosed |
| US-4468402-A | Carbostyril derivatives, process for producing the same and cardiotonic compositions containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-08-28 | — | — | US | disclosed |
| US-4454130-A | CARDIOTONIC, HYPOTENSIVE AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-06-12 | — | — | US | disclosed |
| US-4438277-A | Hydronaphthalene derivatives | SANKYO COMPANY, LIMITED (JP) | 1984-03-20 | — | — | US | disclosed |
| US-4361515-A | Antihyperlipemic dihydro-ML-236B derivatives, their preparation and use | SANKYO COMPANY, LIMITED (JP) | 1982-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263572-A1 | 3-AMINOALKYL-1,4-DIAZEPAN-2-ONE MELANOCORTIN-5-RECEPTOR ANTAGONISTS | MC5R, MC1R, MC3R | CYP2C19 1402/4885KDM4E 1545/4885ALDH1A1 2430/4885 |
| US-20090221558-A1 | METHODS OF MODULATING THE ACTIVITY OF THE MC5 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR | MC5R, MC1R, MC3R | CYP2C19 1067/4885KDM4E 3039/4885ALDH1A1 2828/4885 |
| US-20130225563-A1 | METHODS OF MODULATING THE ACTIVITY OF THE MC5 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR | MC5R, MC1R, MC3R | CYP2C19 1067/4885KDM4E 3039/4885ALDH1A1 2828/4885 |
| US-20090221557-A1 | 3-AMINOALKYL-1,4-DIAZEPAN-2-ONE MELANOCORTIN-5 RECEPTOR ANTAGONISTS | MC5R, MC1R, MC3R | CYP2C19 1383/4885KDM4E 1387/4885ALDH1A1 2040/4885 |
| US-20120141392-A1 | METHODS OF MODULATING THE ACTIVITY OF THE MC1 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR | MC1R, MC5R, MC3R | CYP2C19 916/4885KDM4E 3952/4885ALDH1A1 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.